<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000600434"><TermName>anti-VEGFR monoclonal antibody</TermName><TermPronunciation>(AN-tee … MAH-noh-KLOH-nul AN-tee-BAH-dee)</TermPronunciation><TermDefinition><DefinitionText>A substance that binds to receptors for a protein called vascular endothelial growth factor (VEGF), which may be found on some types of cancer cells. This may prevent the growth of new blood vessels that tumors need to grow. There are different types of anti-VEGFR monoclonal antibodies being studied in the treatment of cancer. These substances are a type of antiangiogenesis agent and a type of monoclonal antibody.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720609" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anti-VEGFR monoclonal antibody&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720610" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anticuerpo monoclonal anti-RFCEV&quot;" language="es" id="_4"/><SpanishTermName>anticuerpo monoclonal anti-RFCEV</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia que se une a los receptores de una proteína que se llama factor de crecimiento endotelial vascular (FCEV) que se puede encontrar en algunos tipos de células cancerosas. Puede prevenir la formación de vasos sanguíneos nuevos que los tumores necesitan para crecer. Hay distintos tipos de anticuerpos monoclonales anti-RFCEV que están en estudio para el tratamiento del cáncer. Estas sustancias son un tipo de antioangiogénico y un tipo de anticuerpo monoclonal.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-07-17</DateFirstPublished><DateLastModified>2014-11-07</DateLastModified></GlossaryTerm>
